UK biotech Verona Pharma (LSE: VRP) has announced positive headline data from a Phase IIa study on the bronchodilator effect of nebulized RPL554, administered on top of salbutamol and ipratropium bromide, for chronic obstructive pulmonary disease (COPD).
The company believes this could address a multi-million dollar market in providing an answer for patients with COPD, the name for a collection lung conditions including chronic bronchitis, emphysema and chronic obstructive airways disease.
RPL554 is a new inhaled dual PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties in the same molecule. It is currently in development as a nebulized treatment for acute exacerbations in COPD patients in a hospital or for maintenance treatment in a home-care setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze